Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psoriasis

WESTLAKE VILLAGE, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- In order to address a major limitation of today’s most widely used method for gauging severity of plaque psoriasis (the PASI scale), Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), in conjunction with leading psoriasis experts, has developed a...

Click to view original post